Increasing Caregiver Engagement in Juvenile Drug Courts

March 6, 2024 updated by: Medical University of South Carolina

Behavioral Incentives to Increase Caregiver Engagement in Juvenile Drug Courts

The purpose of this study is to test a prize-based contingency management intervention for increasing caregiver engagement in juvenile drug court and adolescent drug treatment, and for achieving the ultimate outcomes of reduced substance use and delinquent behavior among drug court-involved youth.

Study Overview

Detailed Description

Juvenile offenders with substance abuse problems represent a large and underserved population that is at high risk of deleterious outcomes and long-term costs for themselves, their families, communities, and society. Moreover, a high percentage of substance abusing adolescents continue to abuse substances and engage in criminal activity into adulthood. Although one juvenile justice intervention, Juvenile Drug Court (JDC), has emerged as a promising model for reducing drug use and delinquency among youth, its effectiveness is variable. Drug court outcomes may be compromised by the lack of caregiver engagement in JDC processes and adolescent drug treatment. Incorporating easily implemented evidence-based incentive programs in JDCs might improve their effectiveness in reducing youth drug use and re-offending. An extensive body of research supports the critical role that families play in the etiology, maintenance, and treatment of adolescent substance abuse. Although family-based interventions for adolescent substance abuse have been shown to be superior to other treatment modalities, parents must attend treatment and participate in meaningful ways for these superior outcomes to be realized. This randomized clinical trial will examine the efficacy of a prize-based contingency management intervention for increasing caregiver engagement (attendance and participation) in JDC and adolescent drug treatment. This caregiver contingency management intervention (CCM) will be compared with drug court treatment as usual (TAU). Increased caregiver participation is predicted to improve adolescent outcomes (decreased drug use and delinquent behavior). One hundred and eighty youth enrolled in JDC will be randomly assigned along with a parent/caregiver to TAU or CCM. Analyses will examine measures of caregiver engagement in JDC as well as youth substance use (urine drug screens) and delinquent activity. Results from this study will demonstrate the effectiveness of CCM procedures for increasing caregiver attendance and participation in JDC and adolescent drug treatment above and beyond drug court and usual care. If effective, the CCM approach may ultimately be used to enhance JDC outcomes, thereby reducing substance use and recidivism in juvenile offenders served by this promising juvenile justice intervention.

Study Type

Interventional

Enrollment (Actual)

195

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Dayton, Ohio, United States, 45422
        • Montgomer County Juvenile Court, 380 West Second Street
    • Texas
      • Corpus Christi, Texas, United States, 78415
        • Nueces County Juvenile Court/Juvenile Treatment Court

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 89 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria for youth:

  • Involved in juvenile drug court
  • Aged 13-17 years
  • Youth is willing to participate
  • At least one caregiver is willing to participate in the youth's treatment
  • Fluent in English or Spanish

Exclusion Criteria for youth:

  • Diagnosed with intellectual disability or autism spectrum disorder

Inclusion Criteria for caregivers:

  • Caregiver of youth involved in juvenile drug court
  • Caregiver is willing to participate
  • Fluent in English or Spanish

Exclusion Criteria for caregivers:

  • Diagnosed with intellectual disability or autism spectrum disorder

Inclusion Criteria for therapists:

  • Providing substance abuse treatment to a youth in juvenile drug court

Exclusion Criteria for therapists:

  • None

Inclusion Criteria for Juvenile Drug Court Personnel:

  • Personnel working in juvenile drug court

Exclusion Criteria for Juvenile Drug Court Personnel:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Caregiver Contingency Management + Usual Drug Court Treatment
This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
Active Comparator: Usual Drug Court Treatment
This group will receive the standard outpatient substance abuse treatment services provided at JDC.
Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes from baseline to 18 months post-baseline in Youth Urine Drug Screens (measured at 0, 3, 5, 6, 9, 12, and 18 months).
Time Frame: Baseline to 18 months
Number of positive drug screens from toxicology testing with youth for tetrahydrocannabinol (THC), amphetamines, methamphetamines, opiates, cocaine, benzodiazepines, MDMA, and oxycodone.
Baseline to 18 months
Changes from baseline to 18 months post-baseline in Youth Substance Use Frequency and Problems (measured at 0, 1, 2, 3, 4, 5, 6, 9, 12, and 18 months).
Time Frame: Baseline to 18 months
Frequency of substance use and substance-related problems self-reported by youth on the Global Appraisal of Individual Needs.
Baseline to 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes from baseline to 18 months post-baseline in Youth Arrests, Charges, and Convictions.
Time Frame: Baseline to 18 months
Number of youth arrests, charges, and convictions measured via official arrest records.
Baseline to 18 months
Changes from baseline to 18 months post-baseline in Youth Delinquent Behaviors (measured at 0, 3, 5, 6, 9, 12, and 18 months).
Time Frame: Baseline to 18 months
Frequency of delinquent behaviors self-reported by youth using the Self-Report Delinquency Scale.
Baseline to 18 months
Changes from Baseline to 18 months post-baseline in caregiver reports on Youth Internalizing Symptoms and Externalizing Behaviors (measured at 0, 1, 2, 3, 4, 5, 6, 9, 12, and 18 months).
Time Frame: Baseline to 18 months
Frequency of youth's internalizing symptoms and externalizing behaviors measured with the Child Behavior Checklist (caregiver report).
Baseline to 18 months
Changes from Baseline to 18 months post-baseline in youth reports on Youth Internalizing Symptoms and Externalizing Behaviors (measured at 0, 1, 2, 3, 4, 5, 6, 9, 12, and 18 months).
Time Frame: Baseline to 18 months
Frequency of youth's internalizing symptoms and externalizing behaviors measured with the Brief Problem Checklist (youth report).
Baseline to 18 months
Changes from baseline to post-treatment in Caregiver Substance Use Problems.
Time Frame: Baseline through treatment completion, an average of 4 months
Frequency and severity of substance use problems self-reported by caregivers on the Addiction Severity Index.
Baseline through treatment completion, an average of 4 months
Changes from baseline to post-treatment in Caregiver Depressive Symptoms.
Time Frame: Baseline through treatment completion, an average of 4 months
Frequency and severity of depressive symptoms self-reported by caregivers on the Beck Depression Inventory.
Baseline through treatment completion, an average of 4 months
Changes from baseline to post-treatment in Therapist-Family Working Alliance (measured at 1, 2, 3, and 4 months, as well as post-treatment).
Time Frame: Baseline through treatment completion, an average of 4 months
Levels of alliance during treatment reported by therapists, caregivers, and youth on the Working Alliance Inventory.
Baseline through treatment completion, an average of 4 months
Changes from baseline to post-treatment in Caregiver Treatment Attendance and Activity Completion (measured at 1, 2, 3, and 4 months, as well as post-treatment).
Time Frame: Baseline through treatment completion, an average of 4 months
Frequency of caregiver attendance at their youth's substance use treatment sessions and completion of therapeutic activities reported by therapists on the Session Tracking Sheet.
Baseline through treatment completion, an average of 4 months
Changes from baseline to the end of JDC involvement in Caregiver Attendance at JDC Sessions.
Time Frame: Baseline through the end of JDC involvement, an average of 12 months
Frequency of caregiver attendance at their youth's JDC sessions reported by JDC personnel on the JDC Attendance Form.
Baseline through the end of JDC involvement, an average of 12 months
Rates of Treatment Completion.
Time Frame: Up to 4 months on average
Rates of youth treatment completion reported by therapists using the Treatment Termination Form.
Up to 4 months on average
Levels of Satisfaction with Treatment and JDC.
Time Frame: Up to 4 months on average
Levels of satisfaction with substance use treatment and JDC reported by caregivers and youth on the Client Satisfaction Questionnaire.
Up to 4 months on average
Changes from baseline to post-treatment in Caregiver Perceptions of Incentive Programs.
Time Frame: Baseline through treatment completion, an average of 4 months
Ratings by caregivers on perceptions of incentive-based interventions as measured by the Provider Survey of Incentives.
Baseline through treatment completion, an average of 4 months
Changes from baseline to 36 months post-baseline in Therapist and JDC Personnel Perceptions of Incentive Programs (measured at 0, 12, 24, and 36 months).
Time Frame: Baseline to 36 months
Ratings by therapists and JDC personnel on perceptions of incentive-based interventions as measured by the Provider Survey of Incentives.
Baseline to 36 months
Reports at post-treatment on Youth and Caregiver Attitudes Toward Incentive Programs.
Time Frame: Up to 4 months on average
Youth and caregiver attitudes toward incentive programs as measured during qualitative interviews.
Up to 4 months on average
Changes from baseline to 36 months post-baseline in Therapist and JDC Personnel Attitudes Toward Incentive Programs (measured at 0, 12, 24, and 36 months).
Time Frame: Baseline to 36 months
Therapist and JDC personnel attitudes toward incentive programs as measured during qualitative interviews.
Baseline to 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Phillippe Cunningham, Ph.D., Medical University of South Carolina
  • Principal Investigator: David Ledgerwood, Ph.D., Wayne State University
  • Study Director: Stacy Ryan, Ph.D., The University of Texas Health Science Center at San Antonio

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 13, 2017

Primary Completion (Actual)

December 12, 2023

Study Completion (Actual)

December 12, 2023

Study Registration Dates

First Submitted

February 8, 2017

First Submitted That Met QC Criteria

February 9, 2017

First Posted (Actual)

February 14, 2017

Study Record Updates

Last Update Posted (Actual)

March 7, 2024

Last Update Submitted That Met QC Criteria

March 6, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • R01MD011322 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance Abuse

Clinical Trials on Caregiver Contingency Management + Usual Drug Court Treatment

3
Subscribe